Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use

1. A compound according to Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

n is an integer from 2 to 6; and

R 1 is selected from H, methyl, ethyl, and C 3-6 alkyl,

provided that when R 1 is H, then n is 4, 5, or 6.

2. The compound according to claim 1 , wherein R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, pentyl-2-yl, 2-methylbutyl, isopentyl, 3-methylbutan-2-yl, neopentyl, tert-pentyl, n-hexyl, hexan-2-yl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 3-methylpentan-2-yl, 4-methylpentan-2-yl, 2,3-dimethylbutyl, or 3,3-dimethylbutyl.

3. The compound according to claim 1 , wherein R 1 is methyl.

4. The compound according to claim 1 , wherein the compound is a pharmaceutically acceptable salt.

5. The compound according to claim 1 , wherein the compound is a HCl salt.

6. A compound selected from the-group consisting of:

7. A compound according to Formula (IIIc):

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 7 , wherein the compound is a HCl salt.

9. A pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

n is an integer from 2 to 6; and

R 1 is selected from H methyl, ethyl, and C 3-6 alkyl.

10. The pharmaceutical composition according to claim 9 , wherein R 1 is methyl.

11. The pharmaceutical composition according to claim 9 , wherein R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, pentyl-2-yl, 2-methylbutyl, isopentyl, 3-methylbutan-2-yl, neopentyl, tert-pentyl, n-hexyl, hexan-2-yl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 3-methylpentan-2-yl, 4-methylpentan-2-yl, 2,3-dimethylbutyl, or 3,3-dimethylbutyl.

12. The pharmaceutical composition according to claim 9 , wherein the compound is a pharmaceutically acceptable salt.

13. The pharmaceutical composition according to claim 9 , wherein the compound is a HCl salt.

14. A pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a therapeutically effective amount of a compound selected from the group consisting of:

15. A pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a therapeutically effective amount of a compound of Formula (IIIc):

or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition according to claim 15 , wherein the compound is a HCl salt.

17. The pharmaceutical composition according to claim 9 , wherein the composition is suitable for oral administration.

18. The pharmaceutical composition according to claim 9 , wherein the compound is present in an amount that is effective for the treatment of a disease chosen from multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

19. A method for treating in a mammal in need thereof a disease or condition which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

n is an integer from 2 to 6; and

R 1 is selected from H, methyl, ethyl, and C 3-6 alkyl, and

wherein the disease or condition is chosen from psoriasis, psoriasis vulgaris, guttate psoriasis, hyperkeratosis, arthritis, inflammatory arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (IBD), irritable bowel disorder, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Bechet's colitis, indeterminate colitis, asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, asbestosis, pneumoconiosis, pulmonary neoplasms, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinopathia pigmentosa, mitochondrial encephalomyopathy, cardiac insufficiency, left ventricular insufficiency, myocardial infarction, angina pectoris, ischemia and reperfusion injury, transplantation rejection, AGE-induced genome damage, NF-κB mediated diseases, rheumatic, eczema, sarcoidosis, granuloma annulare, autoimmune carditis, acute disseminated encephalomyelitis, Addison's disease, alopecia greata, ankylosing spondylitis, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, bullous pemphigoid, Bechet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hidradenitis suppurativea, Kawasaki disease, IgA neuropathy, idiopathic thrombocytopenic purpura, interstitial cystitis, lupus erythematosus, mixed connective tissue disease, morphea, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anemia, polymyositis, primary biliary cirrhosis, schizophrenia, scleroderma, Sjogren's syndrome, stiff person syndrome, temporal arteritis, ulcerative colitis, vasculitis, vitiligo, myasthenia gravis, or Wegener's granulomatosis.

20. The method according to claim 19 , wherein R 1 is methyl.

21. The method according to claim 19 , wherein R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, pentyl-2-yl, 2-methylbutyl, isopentyl, 3-methylbutan-2-yl, neopentyl, tert-pentyl, n-hexyl, hexan-2-yl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 3-methylpentan-2-yl, 4-methylpentan-2-yl, 2,3-dimethylbutyl or 3,3-dimethylbutyl.

22. The method according to claim 19 , wherein the compound is a pharmaceutically acceptable salt.

23. The method according to claim 19 , wherein the compound is a HCl salt.

24. A method for treating in a mammal in need thereof a disease or condition which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to Formula (IIIc):

or a pharmaceutically acceptable salt thereof,

wherein the disease or condition is chosen from psoriasis, psoriasis vulgaris, guttate psoriasis, hyperkeratosis, arthritis, inflammatory arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (IBD), irritable bowel disorder, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Bechet's colitis, indeterminate colitis, asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, asbestosis, pneumoconiosis, pulmonary neoplasms, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinopathia pigmentosa, mitochondrial encephalomyopathy, cardiac insufficiency, left ventricular insufficiency, myocardial infarction, angina pectoris, ischemia and reperfusion injury, transplantation rejection, AGE-induced genome damage, NF-κB mediated diseases, rheumatic, eczema, sarcoidosis, granuloma annulare, autoimmune carditis, acute disseminated encephalomyelitis, Addison's disease, alopecia greata, ankylosing spondylitis, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, bullous pemphigoid, Bechet's disease, celiac disease, Chagas disease, dermatomyositis, diabetes mellitus type I, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hidradenitis suppurativea, Kawasaki disease, IgA neuropathy, idiopathic thrombocytopenic purpura, interstitial cystitis, lupus erythematosus, mixed connective tissue disease, morphea, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anemia, polymyositis, primary biliary cirrhosis, schizophrenia, scleroderma, Sjogren's syndrome, stiff person syndrome, temporal arteritis, ulcerative colitis, vasculitis, vitiligo, myasthenia gravis, or Wegener's granulomatosis.

25. The method according to claim 24 , wherein the compound is a HCl salt.

26. The method according to claim 24 , wherein the disease or condition is chosen from multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis.

27. The method according to claim 19 , wherein the disease or condition is chosen from psoriasis, psoriasis vulgaris, guttate psoriasis, hyperkeratosis, arthritis, inflammatory arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, inflammatory bowel disease (IBD), irritable bowel syndrome, Crohn's Disease, Ulcerative Colitis, collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Bechet's colitis, indeterminate colitis, asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, asbestosis, pneumoconiosis, pulmonary neoplasms, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, or amyotrophic lateral sclerosis.

28. The method according to claim 24 , wherein the disease or condition is chosen from psoriasis, psoriasis vulgaris, guttate psoriasis, hyperkeratosis, arthritis, inflammatory arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, inflammatory bowel disease (IBD), irritable bowel syndrome, Crohn's Disease, Ulcerative Colitis, collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Bechet's colitis, indeterminate colitis, asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, asbestosis, pneumoconiosis, pulmonary neoplasms, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, or amyotrophic lateral sclerosis.

29. The method according to claim 19 , wherein the disease or condition is chosen from multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis.